Karyopharm Therapeutics Long Term Debt

As of the most recent data (June 2026), KPTI shows a long-term debt of $210M. That compares with $93M in the prior-year period — up 130.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KPTI's long-term debt is now $210M (was $93M) — a 130.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Karyopharm Therapeutics is outperforming or lagging.

Tracking KPTI's long-term debt over time shows whether Karyopharm Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $210M That compares with $93M in the prior-year period — up 130.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Karyopharm Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $210M) with ownership activity and broader fundamentals.

Karyopharm Therapeutics's long-term debt is $210M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.